Treatment and transplant news
Once a blood cancer treatment is developed, it needs to be approved for sale in Australia and subsidised, or ‘listed’, otherwise the cost for the treatment can be unaffordable for many patients. The Medical Services Advisory Committee (MSAC) or Pharmaceutical Benefits Advisory Committee (PBAC) appraises a new treatment and provides advice to the Government on whether it should be publicly funded. This includes seeking consumer comments. Here’s a summary of recent new and recommended listings for blood cancer treatments. The Leukaemia Foundation provided advice and consumer comments to PBAC/MSAC in support of these therapies being available to patients.
- Advocacy and policy
- Treatments and side-effects